Skip to content

John Strang

6 papers in the library · 20 citations · publishing 2022-2026

Papers

Sort Most recent Most cited

Insight into cannabis use disorder in people with psychotic disorders

BJPsych Open August 25, 2026 Edward Chesney, Millie Lloyd, Sébastien Brodeur et al.

BACKGROUND: Cannabis use is common in people with psychosis and is associated with poor outcomes. AIMS: To assess insight into cannabis use disorder, perceptions about how cannabis use influences mental health and the desire to change cannabis use among people with psychotic disorders. METHOD: Adults with a psychotic disorder and comorbid cannabis use disorder were asked about the impact of...

The subjective effects of △9-tetrahydrocannabinol: A systematic review and dose-response meta-regression.

Neuroscience & Biobehavioral Reviews June 3, 2026 Isabella Goodwin, Dominic Oliver, Edward Chesney et al.

Global shifts towards the liberalisation of cannabis policies have increased the potency of cannabis products, alongside their accessibility, diversity, and the number of inexperienced cannabis consumers. There is a lack of systematic evidence on the subjective effects of cannabis' main psychoactive compound, Δ9-tetrahydrocannabinol (THC). We systematically reviewed and meta-analysed data from...

Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial.

Neuropsychopharmacology November 2025 Edward Chesney, Dominic Oliver, Ananya Sarma et al.

In patients with schizophrenia, cannabis use exacerbates symptoms and can lead to a relapse of psychosis. Some experimental studies in healthy volunteers suggest that pre-treatment with cannabidiol (CBD) may reduce these effects, but others do not. Here, we investigated whether pre-treatment with CBD ameliorates the acute adverse effects of cannabis in patients with schizophrenia. Participants...

Cannabidiol does not attenuate acute delta-9-tetrahydrocannabinol-induced attentional bias in healthy volunteers: A randomised, double-blind, cross-over study.

Addiction February 2024 Dominic Oliver, Amir Englund, Edward Chesney et al.

To test how attentional bias and explicit liking are influenced by delta-9-tetrahydrocannabinol (THC) and whether these effects are moderated by cannabidiol (CBD). Double-blind, randomised, within-subjects cross-over study. NIHR Wellcome Trust Clinical Research Facility at King's College Hospital, London, United Kingdom. Forty-six infrequent cannabis users (cannabis use <1 per week). Across...

Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover Study

Cannabis and Cannabinoid Research December 9, 2022 Lucy Chester, Amir Englund, Edward Chesney et al. 20 citations

Background: The effects of cannabis are thought to be mediated by interactions between its constituents and the endocannabinoid system. Delta-9-tetrahydrocannabinol (THC) binds to central cannabinoid receptors, while cannabidiol (CBD) may influence endocannabinoid function without directly acting on cannabinoid receptors. We examined the effects of THC coadministered with different doses of CBD...

Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios

Neuropsychopharmacology November 16, 2022 Amir Englund, D. Oliver, Edward Chesney et al.

As countries adopt more permissive cannabis policies, it is increasingly important to identify strategies that can reduce the harmful effects of cannabis use. This study aimed to determine if increasing the CBD content of cannabis can reduce its harmful effects. Forty-six healthy, infrequent cannabis users participated in a double-blind, within-subject, randomised trial of cannabis preparations...